Biogen (NASDAQ:BIIB) said it continues to expect full-year 2023 adjusted EPS of $15 to $16. Analysts polled by Capital IQ are expecting adjusted EPS of $15.43. Revenue for the year is expected to decline by mid-single-digit percentage from a year earlier.